Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Mayne Pharma Group inks licensing deal with Indian pharma  Join our daily free Newsletter

MENAFN - ProactiveInvestors - Australia - 01/11/2012

No. of Ratings : 0
Add to Mixx!


 


(MENAFN - ProactiveInvestors - Australia) Mayne Pharma Group (ASX: MYX) has signed a licensing and distribution agreement with India's Intas Pharmaceuticals for a large range of injectable products for the Australian market.

Mayne will initially gain rights to 11 hospital products with a market value of around 73 million per annum.

The company expects to file these products with the Therapeutic Goods Administration (TGA) during the 2013 calendar year.

Mayne has also secured a right of first refusal for the exclusive distribution of another 30 pipeline injectable products across a range of therapeutic areas with current market sales of 140 million per annum.

To date, there are no generic equivalents to 15 of these pipeline products and the company expects several of these will be the first generic versions approved.

All products will be developed and supplied by Intas from their TGA and US Food and Drug Administration approved facilities.

Intas is one of the leading vertically-integrated pharmaceutical development, manufacturing and marketing companies headquartered in India.

It is among the top pharmaceutical companies in India and has a presence in over 50 countries worldwide.


Metrics' acquisition

Following the completion of the acquisition of Metrics in mid-November, Mayne plans to seek TGA approval for a number of Metrics' products in Australia.

The launch of these new products is expected to lead to significant revenue and margin uplift of the Mayne Pharma Australia business over the coming years.

Metrics has 11 pipeline products of which two have been filed with the FDA and a further four are to be filed during 2012.

All pipeline products are targeting FDA approval by the end of 2014 with two approvals expected in 2013.

Last month, Mayne entered into a binding agreement to acquire privately owned, U.S.-based Metrics, which provides the company with direct access to the world's largest pharmaceutical market, the U.S.

The combined business will have 17 products in development targeting markets with annual sales of US4.5 billion.

Metrics is a leading provider of contract pharmaceutical development services in the U.S. with a substantial existing product portfolio and pipeline.

The company has a strong financial track record having delivered sales and EBITDA for the 2012 financial year of US51.6 million and US16.1 million respectively. Its growing generics portfolio will drive significant future EBITDA growth.

 






  MENA News Headlines


 
Click to Apply






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help